1. |
Jemal A, Siegel R, Ward E, et al. Cancer statistics [J]. CA Cancer J Clin, 2007, 57(1): 43-66.
|
2. |
万德森. 临床肿瘤学[M]. 2版. 北京:科学出版社, 2005: 348-349.
|
3. |
徐瑞华, 陈晓勤. 结肠癌辅助化学治疗的共识与争议[J]. 内科理论与实践, 2009, 4(1): 32-36.
|
4. |
Sternberg A, Sibirsky O, Cohen D, et al. Validation of a new classification system for curatively resected colorectal adenocarcinoma[J]. Cancer, 1999, 86(5): 782-792.
|
5. |
Gravalos C, Salut A, García-Girón C, et al. A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer[J]. Clin Transl Oncol, 2012, 14(8): 606-612.
|
6. |
孙燕,管忠震,金懋林,等. 奥沙利铂单药或与氟尿嘧啶-甲酰四氢叶酸联合应用治疗晚期大肠癌Ⅱ期临床试用报告[J]. 癌症, 1999, 18(3): 237-240.
|
7. |
Cassidy J, Tabernero J, Twelves C, et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer[J]. J Clin Oncol, 2004, 22(11): 2084-2091.
|
8. |
Chai H, Pan J, Zhang X, et al. ERCC1 C118T associates with response to FOLFOX4 chemotherapy in colorectal cancer patients in Han Chinese[J]. Int J Clin Exp Med, 2012, 5(2): 186-194.
|
9. |
Iqbal S, Lenz HJ. Integration of novel agents in the treatment of colorectal cancer[J]. Cancer Chemother Pharmacol, 2004, 54(Suppl 1): S32-S39.
|
10. |
Díaz-Rubio E, Evans TR, Tabemero J, et al. Capecitabine (Xeloda) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors[J]. Ann Oncol, 2002, 13(4): 558-565.
|
11. |
Walko CM, Lindley C. Capecitabine: a review[J]. Clin Ther, 2005, 27(1): 23-44.
|
12. |
Patel PA. Evolution of 5-fluorouracil-based chemoradiation in the management of rectal cancer[J]. Anticancer Drugs, 2011, 22(4): 311-316.
|
13. |
Davies JM, Goldberg RM. Treatment of metastatic colorectal cancer[J]. Semin Oncol, 2011, 38(4): 552-560.
|
14. |
Madi A, Fisher D, Wilson RH, et al. Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial[J]. Br J Cancer, 2012, 107(7): 1037-1043.
|
15. |
Salazar R, Navarro M, Losa F, et al. Phase Ⅱ study of preoperative radiotherapy and concomitant weekly intravenous oxaliplatin combined with oral capecitabine for stages Ⅱ-Ⅲ rectal cancer[J]. Clin Transl Oncol, 2012, 14(8): 592-598.
|
16. |
Wehler TC, Cao Y, Galle PR, et al. Combination therapies with oxaliplatin and oral capecitabine or intravenous 5-FU show similar toxicity profiles in gastrointestinal carcinoma patients if hand-food syndrome prophylaxis is performed continuously[J]. Oncol Lett, 2012, 3(6): 1191-1194.
|